CEO Awarded $169K Bonus for 2025 Amidst Company's Financial Distress
RKDA sits 16% above its 52-week low of $0.63.
Summary
Arcadia Biosciences disclosed a $169,000 discretionary cash bonus for CEO Thomas J. Schaefer for 2025, a significant payout for a company facing severe financial distress and recent dilutive capital raises.
Key Events · Executive and Board Changes · RKDA
-
CEO Discretionary Bonus Approved
CEO Thomas J. Schaefer was approved for a $169,000 discretionary cash bonus for his 2025 services, finalized on July 1, 2026. This amount was previously undeterminable and is now disclosed.
-
Updated 2025 Compensation Table
The filing includes an updated 2025 Summary Compensation Table reflecting the bonus, bringing Mr. Schaefer's total compensation for 2025 to $473,058.
-
Annual Meeting Date Set
The 2026 annual meeting of stockholders is scheduled for September 10, 2026. The deadline for shareholder proposals and director nominations is July 13, 2026, due to a change in the meeting date.
Analysis · RKDA · Energy & Transportation
This 8-K reveals the final 2025 bonus amount for CEO Thomas J. Schaefer, which was previously undeterminable. The $169,000 discretionary cash bonus, approved on July 1, 2026, is a substantial sum for a company with a market capitalization of approximately $1.6 million. This disclosure comes shortly after the company reported a significant net loss, reiterated a going concern warning, and defaulted on debt in May, followed by a dilutive $4 million private placement in June to secure crucial capital. The decision to award such a bonus amidst severe financial distress and recent shareholder dilution raises concerns about executive compensation practices and capital allocation. Additionally, the company announced its 2026 annual meeting for September 10, 2026, and updated the deadlines for shareholder proposals and director nominations, a routine administrative update.
At the time of this filing, RKDA was trading at $0.73 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.63 to $6.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.